Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
复制标题
DOI：
10.1002/advs.202101176
复制
发表时间：
2021-11
期刊：
影响因子：
--
通讯作者：
Deng C
中科院分区：
文献类型：
--
作者：
Chen P;Zhang X;Ding R;Yang L;Lyu X;Zeng J;Lei JH;Wang L;Bi J;Shao N;Shu D;Wu B;Wu J;Yang Z;Wang H;Wang B;Xiong K;Lu Y;Fu S;Choi TK;Lon NW;Zhang A;Tang D;Quan Y;Meng Y;Miao K;Sun H;Zhao M;Bao J;Zhang L;Xu X;Shi Y;Lin Y;Deng C
大多数晚期乳腺癌表现出侵袭性，缺乏有效的抗癌选择。在此，患者衍生有机化合物(PDO)的开发被描述为一个实时平台，以探索难治性乳腺癌个体化治疗的可行性。从乳腺癌组织中成功地产生了PDO，包括经过大量处理的标本。PDO的微管靶向药物敏感反应信号预测辅助化疗治疗的浸润性乳腺癌的远距离无复发生存率得到改善。进一步证明，PDO药物表型能反映相应患者既往的治疗反应。最后，作为临床案例研究，所有接受至少一种药物判定为PDO敏感的患者都取得了良好的疗效。总之，PDO模型被开发为一个有效的体外评估患者特异性药物敏感性的平台，可以指导晚期乳腺癌患者的个体化治疗决策。晚期乳腺癌患者迫切需要个性化治疗。从乳腺癌组织中可以产生病人衍生的有机化合物(PDO)，用于高效的抗癌药物的鉴定。PDO药物表型分型不仅可以反映患者既往的治疗反应，而且可以作为一个及时的平台来指导难治性疾病的个体化治疗。
Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient‐derived organoids (PDOs) is described as a real‐time platform to explore the feasibility of tailored treatment for refractory breast cancers. PDOs are successfully generated from breast cancer tissues, including heavily treated specimens. The microtubule‐targeting drug‐sensitive response signatures of PDOs predict improved distant relapse‐free survival for invasive breast cancers treated with adjuvant chemotherapy. It is further demonstrated that PDO pharmaco‐phenotyping reflects the previous treatment responses of the corresponding patients. Finally, as clinical case studies, all patients who receive at least one drug predicate to be sensitive by PDOs achieve good responses. Altogether, the PDO model is developed as an effective platform for evaluating patient‐specific drug sensitivity in vitro, which can guide personal treatment decisions for breast cancer patients at terminal stage. Personalized therapies are urgently needed for patients with advanced breast cancers. Patient‐derived organoids (PDOs) can be generated from breast cancer tissues for the identification of anticancer drugs with high efficacy. PDO pharmaco‐phenotyping can not only reflect the previous treatment responses of patients, but also serve as an in‐time platform to guide tailored therapy for the refractory disease.
登录
查看更多内容
DOI：
10.1001/jama.2011.593
发表时间：
2011-05-11
期刊：
JAMA
影响因子：
--
作者：
Hatzis C;Pusztai L;Valero V;Booser DJ;Esserman L;Lluch A;Vidaurre T;Holmes F;Souchon E;Wang H;Martin M;Cotrina J;Gomez H;Hubbard R;Chacón JI;Ferrer-Lozano J;Dyer R;Buxton M;Gong Y;Wu Y;Ibrahim N;Andreopoulou E;Ueno NT;Hunt K;Yang W;Nazario A;DeMichele A;O'Shaughnessy J;Hortobagyi GN;Symmans WF
通讯作者：
Symmans WF
影响因子：
12.3
作者：
Blokzijl F;Janssen R;van Boxtel R;Cuppen E
通讯作者：
Cuppen E
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
14.8
作者：
Cattaneo CM;Dijkstra KK;Fanchi LF;Kelderman S;Kaing S;van Rooij N;van den Brink S;Schumacher TN;Voest EE
通讯作者：
Voest EE
DOI：
10.1093/bioinformatics/btr670
发表时间：
2012-02-01
期刊：
Bioinformatics (Oxford, England)
影响因子：
--
作者：
Boeva V;Popova T;Bleakley K;Chiche P;Cappo J;Schleiermacher G;Janoueix-Lerosey I;Delattre O;Barillot E
通讯作者：
Barillot E